asco gu24 special: assoc. prof. barata discusses the results of keynote-564 and checkmate-914
Published 3 months ago • 35 plays • Length 10:51Download video MP4
Download video MP3
Similar videos
-
9:29
keynote-564 study
-
1:01
asco gu23 toni choueiri, md: keynote-564 subgroup analysis | dana-farber cancer institute
-
1:50
keynote 564 update
-
1:00
adjuvant pembrolizumab in kidney cancer from keynote 564
-
1:37:50
a complex lcx-om bifurcation by tak w. kwan
-
1:01:00
health and humanity | q a
-
30:15
understanding stomach cancer: expert q&a
-
5:51
how does keynote-564 open the door for new adjuvant approaches?
-
8:33
keynote-564, checkmate 9er, and more: where do we stand with advanced and metastatic rcc?
-
0:35
the latest developments in adjuvant therapy for rcc
-
3:18
rcc & penile cancer at asco gu: kn-564, neoavax & pericles
-
4:12
kidney cancer at esmo 2022: keynote-564 and prosper
-
5:33
keynote-564: pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with...
-
0:56
dr. alexander kutikov on options afforded to kidney cancer patient
-
3:03
adjuvant pembrolizumab improves rcc disease-free survival | toni choueiri
-
0:43
hot topics in rcc at asco gu 2023
-
1:42
dana-farber cancer institute: toni k. choueiri, md (kidney cancer research at asco gu21)
-
2:01
colonoscopy patient tami schwenk on family history of cancer
-
2:54
jack teplitsky
-
3:54
2021 october author interview- 2021 october author interview-motohiko kato and mari mizutani
-
1:03
meet alexander kutikov, md, facs - fox chase cancer center (english)
-
1:03
potential of adjuvant therapy for rcc